Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 201 to 225 of 2013

TitleReference numberPublishedLast updated
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitisTA1096
Benralizumab for treating severe eosinophilic asthmaTA565
Berotralstat for preventing recurrent attacks of hereditary angioedemaTA738
Beta interferons and glatiramer acetate for treating multiple sclerosisTA527
Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollenTA1087
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinomaTA178
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancerTA118
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)TA148
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)TA436
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)TA353
Bevacizumab gamma for treating wet age-related macular degenerationTA1022
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancerTA214
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancerTA263
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancerTA285
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancerTA212
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancerTA284
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)TA560
Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapseHTG539
Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritisTA918
Bimekizumab for treating active psoriatic arthritisTA916
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)TA1028
Bimekizumab for treating moderate to severe plaque psoriasisTA723
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancerHTG659
Biodegradable subacromial spacer insertion for rotator cuff tearsHTG702
Biomarker tests to help diagnose preterm labour in women with intact membranesHTG476

Results per page

  1. 10
  2. 25
  3. 50
  4. All